Skip to main content

OrbiMed Advisors LLC

SEC CIK
0001055951
Latest filing
Aug 14, 2026

KROS holding history

Keros Therapeutics, Inc. in every 13F filed by OrbiMed Advisors LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

KROS overviewAll 13F holders of KROSFull Q2 2026 holdings

Shares (Q2 2026)
759,155
Value
$8.12M
% of portfolio
0.2%
Quarters held
22
Since Q1 2021
Holdings of KROS by OrbiMed Advisors LLC, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026759,155$8.12M0.2%00.0%UnchangedHolders
Q1 2026759,155$8.38M0.2%−45,057−5.6%ReducedHolders
Q4 2025804,212$16.4M0.3%−214,522−21.1%ReducedHolders
Q3 20251,018,734$16.1M0.4%00.0%UnchangedHolders
Q2 20251,018,734$13.6M0.3%00.0%UnchangedHolders
Q1 20251,018,734$10.4M0.2%00.0%UnchangedHolders
Q4 20241,018,734$16.1M0.3%00.0%UnchangedHolders
Q3 20241,018,734$59.2M1.1%−250,000−19.7%ReducedHolders
Q2 20241,268,734$58.0M1.2%00.0%UnchangedHolders
Q1 20241,268,734$84.0M1.6%00.0%UnchangedHolders
Q4 20231,268,734$50.4M1.0%−246,000−16.2%ReducedHolders
Q3 20231,514,734$48.3M1.1%00.0%UnchangedHolders
Q2 20231,514,734$60.9M1.2%−164,683−9.8%ReducedHolders
Q1 20231,679,417$71.7M1.4%00.0%UnchangedHolders
Q4 20221,679,417$80.6M1.5%00.0%UnchangedHolders
Q3 20221,679,417$63.2M1.3%00.0%UnchangedHolders
Q2 20221,679,417$46.4M0.9%00.0%UnchangedHolders
Q1 20221,679,417$91.3M1.5%00.0%UnchangedHolders
Q4 20211,679,417$98.3M1.3%00.0%UnchangedHolders
Q3 20211,679,417$66.4M0.7%00.0%UnchangedHolders
Q2 20211,679,417$71.3M0.7%00.0%UnchangedHolders
Q1 20211,679,417$103.4M1.0%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.